5 Must-Read Analyst Questions From Integra LifeSciences's Q2 Earnings Call

Integra LifeSciences’ second quarter results reflected steady execution amid ongoing operational transformation efforts. Management attributed performance to meaningful progress on its Compliance Master Plan and remediation actions, as well as strong demand for key products like Integra Skin. CEO Mojdeh Poul highlighted, “We completed assessments at all of our internal manufacturing sites ahead of schedule, with no new shipholds identified.” The company’s operational focus and improved production output helped counteract the headwinds from supply disruptions and ongoing remediation costs.

Is now the time to buy IART? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Integra LifeSciences’s Q2 Earnings Call

• Vikramjeet Singh Chopra (Wells Fargo): asked about the impact of CMS’s proposed 2026 reimbursement changes for skin substitutes. CEO Mojdeh Poul responded that most exposure is in acute care settings, so short-term risk is limited, but long-term opportunities exist for evidence-backed products.
• Vikramjeet Singh Chopra (Wells Fargo): also inquired about the implied Q4 step-up in earnings. CFO Lea Knight explained that normal seasonal lift and anticipated supply recovery will drive higher revenue and EPS in Q4.
• Xuyang Li (Jefferies): questioned the lingering effects of shipholds and risks into 2026. Knight said most shiphold impact is now visible, with no material new holds expected, but remediation will continue into 2026 and further updates will follow.
• Xuyang Li (Jefferies): followed up on the challenge of winning back customers after product holds. Knight stated that most business returns quickly after supply resumes, but reintroducing PriMatrix and SurgiMend will require more effort and time.
• Lilia-Celine Breton Lozada (JPMorgan): probed the lower organic growth guidance and margin outlook. Knight attributed this to market demand softness, private label partner headwinds, and extended remediation timelines, but noted cost controls should support margins.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace and effectiveness of product relaunches for PriMatrix and SurgiMend, (2) improvements in supply chain reliability and inventory rebuilds, and (3) the ongoing impact of cost reduction initiatives on operating margins. Regulatory developments in reimbursement policy and the ability to recapture lost customers will also be important signposts.

Integra LifeSciences currently trades at $13.77, up from $12.37 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.